| Autor: |
R A, Ghayda, C H, Han, K H, Lee, J S, Kim, S E, Kim, S H, Hong, M, Kim, A, Kronbichler, K, Tizaoui, H, Li, A, Koyanagi, L, Jacob, M S, Kim, D K, Yon, S W, Lee, K, Kostev, J I, Shin, J W, Yang, L, Smith |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
European review for medical and pharmacological sciences. 25(6) |
| ISSN: |
2284-0729 |
| Popis: |
Although previous research has reported beneficial effects of statins on infectious diseases, these have yet to be concluded. Therefore, we conducted an umbrella review to provide a comprehensive understanding of the strength of evidence and validity of claimed associations between statins (hydroxymethyl glutaryl-CoA reductase inhibitors) and infectious diseases.We conducted an umbrella review and re-analyzed data from meta-analyses of randomized controlled trials and observational studies on associations between statin use and different infectious diseases such as bacteremia/sepsis and pneumonia. We also evaluated the level of evidence for each re-analyzed outcome based on the criteria using p-values of random and fixed-effects, 95% prediction intervals, small-study effects, between-study heterogeneity, and concordance between the effect estimate of the largest study and summary estimates of the meta-analysis. Moreover, publication bias was also examined.Through a systematic literature search, we obtained 14 eligible articles including 25 meta-analyses. All 4 meta-analyses on overall infection, 3 out of 14 meta-analyses on bacteremia/sepsis, and 5 out of 7 meta-analyses on pneumonia demonstrated that statin use was associated with reduced mortality due to infections (caused by infections). Nonetheless, most significant results only showed a weak level of evidence, and one study with convincing evidence prior to adjustment also showed weak evidence after adjustment.The present review identified a protective effect of statins on infection-related mortality, but all available studies had a weak level of evidence. Therefore, further studies with a strong level of evidence are needed, and it is also necessary to investigate the types of statins and to study clinical outcomes other than mortality to gain further insights. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
